Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
- 1 April 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (4), 441-448
- https://doi.org/10.1023/a:1008301522349
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumoursBritish Journal of Cancer, 1996
- Detection of platinum-DNA adducts by32P-postlabellingNucleic Acids Research, 1995
- Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumoursBiochemical Pharmacology, 1994
- Cisplatin resistance in human cancersPharmacology & Therapeutics, 1991
- Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometryCarcinogenesis: Integrative Cancer Research, 1991
- 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductaseJournal of Medicinal Chemistry, 1991
- The measurement of cisplatin-DNA adduct levels in testicular cancer patientsCarcinogenesis: Integrative Cancer Research, 1988
- Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosidesThe Journal of Organic Chemistry, 1988
- Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.JCI Insight, 1986
- Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitationBiochemistry, 1985